Last reviewed · How we verify
Process E Belatacept
At a glance
| Generic name | Process E Belatacept |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study Using Healthy Volunteers Comparing Belatacept Which Has Been Manufactured By 2 Different Processes (PHASE1)
- A Study to Compare the Pharmacokinetics of Belatacept Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Process C (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Process E Belatacept CI brief — competitive landscape report
- Process E Belatacept updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI